Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tamoxifen Pharmacogenetics in Asian Breast Cancer Women

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Inje University
Information provided by (Responsible Party):
Jae-Gook Shin, Inje University Identifier:
First received: August 12, 2010
Last updated: May 31, 2013
Last verified: May 2013

The clinical outcome of tamoxifen treatment in breast cancer patients may be influenced by the activity of cytochrome P450 enzymes involving in tamoxifen biotransformation.

Poisoning by, Adverse Effect of and Underdosing of Tamoxifen

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Observational Study: Biomarker Research for Tamoxifen Pharmacogenetics Among Asian Breast Cancer Patients

Resource links provided by NLM:

Further study details as provided by Inje University:

Primary Outcome Measures:
  • Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients [ Time Frame: five years ] [ Designated as safety issue: No ]
    Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients

Biospecimen Retention:   Samples With DNA

Blood samples for genotyping and pharmacokinetic analysis

Estimated Enrollment: 1000
Study Start Date: August 2010
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Detailed Description:

The investigators investigated the prognostic and/or predictive value of genetic polymorphisms of enzymes involved in tamoxifen metabolism for the treatment outcome among Asian breast cancer patients.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Breast cancer patients who underwent surgery at Busan Paik Hospital, Inje University


Inclusion Criteria:

  • incident breast cancer patients who underwent surgery

Exclusion Criteria:

  • previous cancer history before breast cancer diagnosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01181518

Contact: Ji-Yeob Choi, Ph.D. 82-51-890-8663

Korea, Republic of
Inje University Recruiting
Busan, Korea, Republic of, 614-735
Contact: Ji-Yeob Choi, Ph.D.    82-51-890-8663   
Principal Investigator: Jae-Gook Shin, MD,PhD         
Sponsors and Collaborators
Inje University
Principal Investigator: JaeGook Shin, MD,PhD Inje University
  More Information

No publications provided

Responsible Party: Jae-Gook Shin, Professor, Inje University Identifier: NCT01181518     History of Changes
Other Study ID Numbers: 09-140
Study First Received: August 12, 2010
Last Updated: May 31, 2013
Health Authority: Korea: Institutional Review Board

Keywords provided by Inje University:
Breast cancer processed this record on February 27, 2015